Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19

Journal of Intensive Care Medicine - Tập 36 Số 3 - Trang 327-333 - 2021
Rajiv Sonti1, C. William Pike2, Nathan K. Cobb1
1Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center, Washington, DC, USA
2Georgetown University School of Medicine, Washington, DC, USA

Tóm tắt

Background: Inhaled pulmonary vasodilators are used as adjunctive therapies for the treatment of refractory hypoxemia. Available evidence suggest they improve oxygenation in a subset of patients without changing long-term trajectory. Given the differences in respiratory failure due to COVID-19 and “traditional” ARDS, we sought to identify their physiologic impact. Methods: This is a retrospective observational study of patients mechanically ventilated for COVID-19, from the ICUs of 2 tertiary care centers, who received inhaled epoprostenol (iEpo) for the management of hypoxemia. The primary outcome is change in PaO2/FiO2. Additionally, we measured several patient level features to predict iEpo responsiveness (or lack thereof). Results: Eighty patients with laboratory confirmed SARS-CoV2 received iEpo while mechanically ventilated and had PaO2/FiO2 measured before and after. The median PaO2/FiO2 prior to receiving iEpo was 92 mmHg and interquartile range (74 – 122). The median change in PaO2/FiO2 was 9 mmHg (-9 – 37) corresponding to a 10% improvement (-8 – 41). Fifty-percent (40 / 80) met our a priori definition of a clinically significant improvement in PaO2/FiO2 (increase in 10% from the baseline value). Prone position and lower PaO2/FiO2 when iEpo was started predicted a more robust response, which held after multivariate adjustment. For proned individuals, improvement in PaO2/FiO2 was 14 mmHg (-6 to 45) vs. 3 mmHg (-11 – 20), p = 0.04 for supine individuals; for those with severe ARDS (PaO2/FiO2 < 100, n = 49) the median improvement was 16 mmHg (-2 – 46). Conclusion: Fifty percent of patients have a clinically significant improvement in PaO2/FiO2 after the initiation of iEpo. This suggests it is worth trying as a rescue therapy; although generally the benefit was modest with a wide variability. Those who were prone and had lower PaO2/FiO2 were more likely to respond.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra051884

10.1097/CCM.0b013e3182a27909

10.1136/bmj.39139.716794.55

10.4187/respcare.02939

10.1378/chest.14-3161

10.1097/TA.0b013e318258431e

10.4187/respcare.05268

10.1177/0885066620906800

10.1177/1060028015595642

Afshari A, 2017, Cochrane Database Syst Rev, 7, CD007733

10.1056/NEJM200005043421801

10.1056/NEJMoa1214103

10.1056/NEJMoa062200

10.1056/NEJMoa1005372

10.1056/NEJMoa1901686

10.1056/NEJMoa1800385

10.1007/s00134-020-06033-2

10.1056/NEJMoa2015432

Fox SE, 2020, Lancet Respir Med, 2213, 30243

10.1016/j.amjcard.2020.06.007

Li Y, 2020, JACC

10.1016/S0140-6736(20)30937-5

10.1007/s00134-020-06022-5

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed January 8, 2020. Available at: https://www.covid19treatmentguidelines.nih.gov/

10.1345/aph.1R540

10.1097/00003246-199811000-00016

10.4269/ajtmh.20-0283

RECOVERY Collaborative Group, 2020, N Engl J Med

10.1016/j.thromres.2020.04.013

10.1111/jth.14869

10.1002/ams2.521

10.1164/rccm.202003-0817LE

10.1016/S2213-2600(20)30304-0

10.1001/jama.291.13.1603

10.1097/00003246-199701000-00010

10.1186/cc6174

ARDS Definition Task Force, 2012, JAMA, 307, 2526

10.1177/0310057X0403200304

10.1378/chest.117.3.819

10.4187/respcare.04271

10.1155/2014/472136

Thông tin
Thông tin xuất bản

Journal of Intensive Care Medicine

Tập 36 Số 3

327-333

Thông tin tác giả